医学部看護学科の庄村教授の論文が「Cancers」に掲載されました。A paper by Shomura M, et al has been accepted by Cancers.

• 肝細胞がんに対するレンバチニブ治療において、甲状腺機能低下症の発現は良好な予後と関連することを明らかにしました。

• We found that an adverse effect of grade 2/3 hypothyroidism was associated with a better prognosis in patients receiving lenvatinib treatment for advanced HCC.

• Shomura M, Okabe H, Sato E, Fukai K, Shiraishi K, Hirose S, Tsuruya K, Arase Y, Anzai K, Kagawa T. Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers (Basel). 2020 Oct 22;12(11):E3078. doi: 10.3390/cancers12113078. PMID: 33105621